The biopharmaceutical company Biopharma plans to launch a plant in Arad, Romania, in late 2027, with an initial investment of EUR85 million, company president Kostyantyn Yefimenko told the Interfax-Ukraine news agency.
“We have already completed construction of the building and will finish installing all utility lines by September 1. We have already ordered the filling line. By the end of June, we will have contracted for the reactor equipment and all other process equipment. We will begin operations in December 2027,” Yefimenko said.
The initial investment in the plant in Arad is EUR85 million; the Romanian project as a whole will consist of four phases of varying sizes. Total investment in the plants in Uzhhorod and Arad is approximately $500 million.
He noted that the company’s development is not focused on a single project.
“Bila Tserkva is our flagship plant. We’re not shifting our focus; we’re developing all of them—Uzhhorod and Arad—and we’ll continue to build in Latin America,” Yefimenko said.
As previously reported, Biopharma plans to launch the first phase of its plant for the production of pharmaceutical products and immunobiological preparations in Uzhhorod in September 2026, which will provide a full cycle of blood plasma processing. The company has already invested EUR67 million in construction; the total cost of the first phase is EUR75 million. According to the plan, the volume of blood plasma-derived drug production in Uzhhorod will be twice that of production in Bila Tserkva, amounting to up to 1.5 million liters of blood plasma per year; the project in Romania is twice as large.
During the “Industrial Evolution: Manufacturing Drives the Economy” forum in Bila Tserkva, Yefimenko also announced that Biopharma had registered its albumin product in Brazil.
Biopharma exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America while continuing to increase its production capacity.
Biopharma, a biopharmaceutical company, plans to launch the first phase of its plant for the production of pharmaceutical products and immunobiological preparations—which will provide a full cycle of blood plasma processing—in Uzhhorod in September. According to the Government Portal, the company has already invested EUR 67 million in construction. The total cost of the first phase is EUR 75 million.
Currently, the main building and the raw materials warehouse have been completed, and the equipment has been installed.
As previously reported, Biopharma had planned to launch the first phase of production in the first half of 2026.
According to the plan, the volume of blood plasma-derived drug production in Uzhhorod will be twice that of production in Bila Tserkva (Kyiv Oblast) and will reach up to 1.5 million liters per year.
Construction of the “Biopharma Plasma” plant in Uzhhorod began in the fall of 2024. The planned investment in the new facility is approximately EUR 80 million. The company’s Uzhhorod plant will focus on exports.
Biopharma exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America, further increasing its capabilities.
Biopharma, a biopharmaceutical company based in Kyiv, will build production facilities to process 3.5 million liters of plasma in 10 years, the company’s president Konstantin Efimenko said.
“In 10 years, we have to build facilities capable of processing 3.5 million liters of plasma to meet the needs of Ukraine, the Balkans, Turkey, and the Middle East. We are working hard for this,” he said at the Kyiv International Economic Forum (KIEF) on Thursday.
Efimenko said that in March 2024, the company began building a plant in Uzhhorod.
“We are launching the plant in Uzhhorod in the first quarter of 2026, we have bought 3.5 hectares of land in the city of Arad, 200 km from Uzhhorod, in Romania, and we will start building the plant in March 2025,” he said.
Efymenko noted that in 2026, Biopharma plans to process 700 thousand liters of plasma at the plant in Bila Tserkva and reach a turnover of $250 million.
“We need to scale up. Our plant in Uzhhorod is two Bila Tserkva, our plant in Arania is two Bila Tserkva,” he said.
As reported, in early October, Efymenko said that the start of construction of the Biopharma plant (Biopharma, Kyiv) for the production of blood products in Romania would depend on the possibility of investment by companies from Ukraine. The cost of the project will be EUR 486 thousand.
In May 2025, the company plans to start installing equipment at the plant under construction in Uzhhorod, with commissioning to begin in April 2026.
Biopharma’s revenue in the first half of 2024 amounted to UAH 1.5 billion.
Biopharma (Kyiv) plans to open a biology school on July 1 in Bila Tserkva (Kyiv region), where the company’s main production facilities are located, said Konstantin Efimenko, president and co-owner of the company, member of the Council for Support of Entrepreneurship under Martial Law (Council of Seven).
“Our goal is to popularize biology at school; create a base for preparing the Ukrainian team for participation in the International Biology Olympiads; organize a place for the practical round of the All-Ukrainian Biology Olympiad; become one of the leaders at the International Olympiads,” Yefymenko wrote on Facebook on Wednesday.
According to him, by July 1, Biopharma plans to create a team of 10 best teachers in various fields of biology, form classes for theoretical and practical classes, and fill them with the necessary equipment, including pH meters, systems for the isolation of RNA/DNA nucleic acids, biological, digital, digital microscopes, immunohistochemistry equipment, CO2 incubators, gas and liquid chromatographs, Dewar cryostorage, etc.
It is expected that classes at the Bioschool will be available for 30-40 best biology students in grades 8-11, and scholarships will be provided for teachers who have taught the winners of the All-Ukrainian Olympiad and winners.
The Bioschool project aims to create a school biology classroom as a product with subsequent installation in Ukrainian schools, as well as online lectures for free access.
Biopharma, a biopharmaceutical company based in Kyiv, plans to triple the number of its plasma centers to 30 by 2027, according to the company’s president Konstantin Efimenko.
“We plan to increase the number of plasma centers. Currently, there are 10 of them, but by 2027 we want to increase their number to 30,” he said during the forum “Dialogues on Sustainability. How Business Develops in Times of War” forum in Kyiv on Thursday.
He also said that since the beginning of the full-scale invasion, the company “has not stopped working for almost a single day.”
In particular, in March 2022, Biopharma built a complex of diesel generator stations with a total capacity of 2 mW and purchased four 10 cubic meters of fuel tanks, built bomb shelters at the plant and in its office in Kyiv.
As reported, in 2020, Biopharma announced plans to invest $20-23 million in the development of a network of plasma centers by 2025 and build plasma and blood centers in every regional center of Ukraine.
Biopharma is exploring the possibility of building a new plant by 2027, the company’s president Konstantin Efimenko said.
“We have already processed almost 300 thousand liters of plasma, the company’s turnover is slightly more than $100 million, and we need to triple the company’s turnover in four years. But it will not be possible to increase capacity further, we need to build a new plant. The new plant should be ready by 2027. To make it ready by 2027, we need to start tomorrow,” he said during the forum “Dialogues on Sustainability. How Business Develops in Times of War” forum in Kyiv on Thursday.
Efymenko also said that Biopharma plans to build a plant in Romania, but this is not a strategy to reduce dependence on Ukraine, but a way to “increase turnover.”
At the same time, Efimenko noted that attracting investments to Ukraine is currently hampered, in particular, by the issues of war risk insurance and the withdrawal of dividends.
“Biopharma is concerned about this issue, but not so much, because we are here with the foundation of the White Church, with the land. We are already here and will be here. But I am worried about other investors coming here, because the question will arise who needs our country,” he said.
As reported, Biopharma plans to triple the number of its plasma centers to 30 by 2027.
